Furthermore, in a first-line setting, the FLAURA study demonstrated that EGFR-mutant advanced NSCLC patients who were treatment-naïve and taking an upfront osimertinib regimen experienced significantly better median PFS and OS than those who had been treated with the first-generation EGFR-TKIs gefitinib and erlotinib [10,11]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.